Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • Bone Marrow & Stem Cell Transplant
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Targeted Therapy
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • Bone Marrow & Stem Cell Transplant
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Targeted Therapy
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

Immuneering to Collaborate with Astellas on Clinical Studies of Investigational CLDN18.2 Programs in Combination with Atebimetinib for Pancreatic Cancer Patients

November 18, 2026

Faeth Therapeutics and Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer

November 18, 2026

Natera Announces Clinical Collaboration with Incyte on Interventional Ph 2 Study in CRC

November 18, 2026

Calytrix Bio enters an agreement to be acquired by Lilly to advance outcomes for patients living with essential thrombocythemia and myelofibrosis

November 18, 2026

Additional Long-Term Follow-Up Data from Ph 2 Study of Safusidenib in IDH1-Mutant Glioma Presented

November 18, 2026

Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044 for Immuno-Oncology

November 11, 2026

Helix 51 Company Saros Therapeutics Receives Second $2 Million Award to Advance Cancer Immunotherapy

November 11, 2026

Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies

November 11, 2026

Zenith Epigenetics and Lilly to collaborate on Registration Enabling Study of ZEN-3694 and Verzenio® (Abemaciclib) in NUT Carcinoma

November 11, 2026

T-Therapeutics announces oversubscribed $133 million Series B financing to achieve clinical proof-of-concept for first-in-class TCR bispecific therapies in cancer and autoimmune disease

November 11, 2026

Novocure enters clinical trial collaboration and supply agreement with Verastem Oncology to evaluate TTFields therapy, chemo and VS-7375 to treat pancreatic cancer

November 4, 2026

Dren Bio Announces $350 Million Financing to Advance Dibotatug Toward Commercialization and Accelerate Development of Broader Pipeline

November 4, 2026

Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044

November 4, 2026

Starton Therapeutics Signs Clinical Trial Agreement with the Stanford School of Medicine to Evaluate STAR-LLD Combo with Novel CAR-T for Multiple Myeloma

November 4, 2026

Alligator Bioscience signs agreement to sell mitazalimab to Biossil

November 4, 2026

Karyopharm announces a planned merger with Ayrmid Ltd

November 4, 2026

Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621

October 28, 2026

Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209

October 28, 2026

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic CRC

October 27, 2026

Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Ph 2/3 Clinical Trial Collaboration to Evaluate Ivonescimab in 1L BTC

October 27, 2026

Vir Biotechnology and Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors

October 20, 2026

Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer

October 20, 2026

Hansoh Pharma Announces Strategic Collaboration and License Agreement With Roche to Advance Novel ADC Portfolio

October 20, 2026

Alentis and PinotBio announce collaboration to develop next-generation ADCs targeting claudin-1

October 20, 2026

Adlai Nortye Enters Clinical Collaboration with Lilly and Merck KGaA to Evaluate Combination of AN4035 and Cetuximab

October 20, 2026
Page1 Page2 Page3 … Page47

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.